Recent analysis of treatment patterns and survival of newly diagnosed patients with glioblastoma in community settings in the USA has shown that the medical community rapidly adjusted to the new standard of treatment—the so-called 'Stupp regimen'. The findings are encouraging, but further research is needed to improve patient survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Yabroff, K. R., Harlan, L., Zeruto, C., Abrams, J. & Mann, B. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro Oncol. 14, 351–359 (2012).
Lacroix, M. et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190–198 (2001).
Sanai, N. & Berger, M. S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 62, 753–766 (2008).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
van den Bent, M. J., Hegi, M. E. & Stupp, R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 42, 582–588 (2006).
Grossman, S. A. et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J. Clin. Oncol. 27, 4155–4161 (2009).
Motomura, K. et al. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117, 1721–1730 (2011).
Butowski, N. et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 13, 1331–1338 (2011).
Gilbert, M. et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract]. J. Clin. Oncol. 29 (Suppl. 15), 2006 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Desjardins, A., Friedman, H. Glioblastoma—community adjusts to new standard of care. Nat Rev Neurol 8, 244–246 (2012). https://doi.org/10.1038/nrneurol.2012.42
Published:
Issue date:
DOI: https://doi.org/10.1038/nrneurol.2012.42
This article is cited by
-
Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
European Journal of Nuclear Medicine and Molecular Imaging (2016)
